A small-scale open-label study of the treatment of canine flea allergy dermatitis with fluralaner.

Background: Fluralaner is an isoxazoline systemic insecticide and acaricide that provides persistent flea-killing activity on dogs for 12 weeks. European and US field studies have shown that fluralaner treatment alleviates the signs of flea allergy dermatitis (FAD) in client-owned dogs.

Hypothesis/objective: To assess the clinical response in FAD affected dogs over the 12-week period following a single oral fluralaner treatment.

An open, self-controlled study on the efficacy of topical indoxacarb for eliminating fleas and clinical signs of flea-allergy dermatitis in client-owned dogs in Queensland, Australia.

Background: Canine flea-allergy dermatitis (FAD), a hypersensitivity response to antigenic material in the saliva of feeding fleas, occurs worldwide and remains a common presentation in companion animal veterinary practice despite widespread availability of effective systemic and topical flea-control products.

Hypothesis/objectives: To evaluate the clinical response in dogs with FAD treated topically with indoxacarb, a novel oxadiazine insecticide.

Animals: Twenty-five client-owned dogs in Queensland, Australia diagnosed with pre-existing FAD on the basis of clinical signs, flea-antigen intradermal and serological tests.